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Steroid Refractory CD4 T Cells in Patients with
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Andrew D. Dick1,2,3
PURPOSE. A discrete subpopulation of steroid refractory (SR)
CD4 T cells has recently been identified in patients with SR
ulcerative colitis (UC). The purpose of this study was to test
whether this subpopulation is also present in patients with
clinically defined SR uveitis. As interleukin (IL)-2 experimen-
tally mediates the SR phenotype, the combined effects of
dexamethasone (Dex) and a range of IL-2 targeting immuno-
suppressive agents were also investigated.
METHODS. Peripheral blood mononuclear cells (PBMCs) from
27 patients with uveitis and 4 normal volunteers were cultured
for 5 days with CD3-CD28 beads. In vitro steroid refractivity or
responsiveness was determined by the presence or absence of
a subpopulation of SR CD4 cells (as previously reported for
UC) that continued to proliferate or not in the presence of Dex.
The patients were concurrently classified by a masked investi-
gator as having clinically SR (threshold for disease reactivation,
10 mg prednisone daily) or steroid sensitive (SS) disease.
RESULTS. There was 78% (21/27) agreement between the in
vitro and clinical classifications of SR and SS disease ( coeffi-
cient 0.56, P 0.002). This finding corresponds to a positive
predictive value of 90% and a negative predictive value of 71%.
In normal volunteers, basiliximab, daclizumab, and AG490
achieved an equivalent augmentation of CD4 cell suppression
in combination with Dex.
CONCLUSIONS. As in UC, patients with SR uveitis have a subpopu-
lation of SR CD4 cells that are a potential target for interven-
tion with anti–IL-2 therapies, including inhibitors of JAK/STAT
signaling. The identification of SR T cells also has potential
clinical application as a biomarker for SR disease. (Invest Oph-
thalmol Vis Sci. 2009;50:4273–4278) DOI:10.1167/iovs.08-3152
Intraocular inflammation (uveitis) is estimated to affect up to115 people per 100,000 in Western populations,1 just under
a quarter of whom will require systemic immunosuppression
for sight-threatening disease.2 Corticosteroids remain the first-
line choice of systemic therapy,3 but their utility is limited by
their side effects, which include centripetal obesity, skin atro-
phy, osteoporosis, diabetes mellitus, hypertension, and mood
disturbance.4 Treatment success is also variable, and it is esti-
mated that up to a third of patients with uveitis are unable to
achieve disease control at tolerable corticosteroid doses.5,6
Unlike ulcerative colitis (UC) or asthma,7,8 there are no
agreed clinical definitions of steroid refractory (SR) disease for
sight-threatening uveitis. The detrimental impact of suboptimal
corticosteroid responses on visual function and quality of life
of patients with uveitis is nonetheless a significant problem, as
is sustained high-dose corticosteroid use.3 This is reflected in
guidance from the Standardization of Uveitis Nomenclature
(SUN) working group, which advocates the adoption of ste-
roid-sparing thresholds as the principle measure of second-line
immunosuppressive drug efficacy.9 Although qualitative,
achieving a reduction in corticosteroid dose is therefore a key
determinant of treatment success, and there is a clear need to
understand the mechanisms that continue to drive inflamma-
tion in patients in whom corticosteroid taper fails.
A new paradigm for SR disease has recently been proposed,
based on preliminary data from patients with UC, in which
glucocorticoid (GC) therapy positively selects SR CD4 T cells
that perpetuate ongoing inflammation.10 The purpose of this
study was to test the hypothesis that patients with SR uveitis
also have a subpopulation of SR CD4 T cells. Furthermore,
given the evidence corroborating interleukin (IL)-2’s mediation
of the SR phenotype,10–15 the effects of a range of immuno-
suppressive agents that target different points in the generation
and action of IL-2 on CD4 T cells were investigated.
METHODS
Study Participants
Twenty-seven patients under the care of the Regional Ocular Inflam-
mation Service at Bristol Eye Hospital for sight-threatening uveitis and
four normal volunteers, were enrolled. The study complied with the
tenets of the Declaration of Helsinki and was reviewed and approved
by the Central and South Bristol Local Research Ethics Committee
(Reference no. 04/Q2006/163). Informed consent was obtained from
all participants.
Clinical Classification of Steroid Responsiveness
As there is no accepted definition of SR disease in uveitis, the consen-
sus from the SUN working group of a threshold of 10 mg prednisone
daily was thus adopted as the standard for distinguishing between
patients with SR and those with steroid-sensitive (SS) disease. To
ensure that this classification was based on a pure corticosteroid
response, independent of the effects of other immunosuppressants,
patients’ clinical records were retrospectively reviewed to establish
the dose of prednisone at which the disease reactivated during their
first cycle of corticosteroid monotherapy. If this was10 mg daily, the
patient was classified as having SR disease, and if it was 10 mg daily,
the patient was classified as having SS disease.
Our standard corticosteroid treatment regimen is 60 mg prednisone
daily for 5 days, 40 mg daily for 1 week, 30 mg daily for 1 week, 20 mg
daily for 2 weeks, 15 mg daily for 2 weeks, and 10 mg daily for 1
month. Subsequent taper is in steps of 1 to 2.5 mg daily.
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PBMC Preparation and Culture
Peripheral blood mononuclear cells (PBMCs) were isolated from whole
blood on a density gradient (Ficoll-Paque Plus; GE Health Care, Pisca-
taway, NJ) and stained with carboxyfluorescein succinimidyl ester
(CFSE; Vybrant CFDA SE, Cell Tracer Kit, V-12883; Molecular Probes,
Eugene, OR) before culture in RPMI 1640 with 5% heat-inactivated fetal
bovine serum (PAA), 100 IU/mL penicillin G, 100 mg/mL streptomy-
cin, and 20 mM HEPES buffer (Invitrogen Life Technologies, Carlsbad,
CA). Cells were seeded in 96-well U-bottomed plates (1 105 per well)
and incubated at 37°C in humidified air with 5% CO2 in the presence
of 106 M dexamethasone (Dex; Sigma-Aldrich, Poole, UK). CD3-
CD28–coated beads (Dynabeads; Dynal Biotech, Oslo, Norway) were
then added (0.25 L/well) to stimulate T-cell proliferation. These
culture conditions were optimized for patients with uveitis by titrating
the concentration of CD3-CD28 beads used to distinguish between
individuals with SR and SS disease, before study enrollment.
CD4 Cell Proliferation
PBMCs were washed after 5 days in culture and were stained with
phycoerythrin-conjugated anti-CD4 (1:400 dilution; Invitrogen Life
Technologies,) and allophycocyanin-conjugated anti-CD3 (1:400 dilu-
tion; Invitrogen Life Technologies). CFSE dilution in CD3CD4 cells
was then quantified by flow cytometry (FACSCalibur; BD Biosciences,
San Diego, CA) and analyzed (CellQuest software; BD Biosciences).16
Dead cells were excluded by using 7-aminoactinomycin (7-AAD; BD
Biosciences).
In Vitro Classification of Steroid Sensitivity
The CFSE profiles of proliferating CD4 cells in cultures from patients
with uveitis were classified as SR or SS based on the presence or
absence of a discrete CFSElow subpopulation, as previously described10
(Fig. 1).
In Vitro Interleukin-2 Inhibition
PBMCs from four normal volunteers were cultured for 5 days in the
presence of 1010 to 106 M Dex and/or any of the following anti–IL-2
agents: 0.1 ng/mL to 1 g/mL tacrolimus (a calcineurin inhibitor;
Astellas Pharma, Ltd., Staines, UK), 1 ng/mL to 100 g/mL basiliximab
(a chimeric anti-CD25 monoclonal antibody [mAb]; Novartis Pharma-
ceuticals, Basel, Switzerland), 1 ng/mL to 100 g/mL daclizumab (a
humanized anti-CD25mAb; Roche Pharmaceuticals, Welwyn Garden
City, UK), and 0.1 to 30 g/mL AG490 (a JAK [janus kinase]/STAT
[signal transducer and activator of transcription] inhibitor; Calbio-
chem, San Diego, CA).17,18 CFSE dilution in CD3CD4 cells was then
quantified by flow cytometry (as just described).
Masked Comparison of Clinical and In Vitro
Classifications of Steroid Sensitivity and
Statistical Analyses
The investigators making the clinical and in vitro classifications of
steroid responsiveness were masked to each other’s findings. Their
degree of agreement was then assessed by calculating the  coeffi-
cient19 (SPSS ver.14.0 for Windows; SPPS, Inc., Chicago, IL). Specific-
ity, sensitivity, and predictive values for SR disease are also reported.
All flow cytometric analyses were conducted using software
(FlowJo; Tree Star Software, San Carlos, CA). For the IL-2 inhibitor
studies, cells exposed to a supratherapeutic concentration of tacroli-
mus (1 mg/mL) did not proliferate, and a marker set on this population
was then applied to all other samples to determine their proportion of
nonproliferated cells, as previously described.10 Statistical comparisons
were then calculated by Mann-Whitney test (GraphPad Prism ver. 4.00
for Windows; GraphPad Software, San Diego, CA).
RESULTS
Characteristics of Study Subjects
Of the 27 patients with sight-threatening intraocular inflamma-
tion, 14 had clinically SR disease (i.e., the threshold for reacti-
vation during their first cycle of corticosteroid monotherapy
was 10 mg prednisone daily), with a median age of 43 years
(vs. 31 years for patients with SS uveitis; Table 1). The distri-
bution of the sexes was similar in both groups, but there was
a higher frequency of intermediate uveitis, classified in accor-
dance with SUN guidance,9 (perhaps reflecting the greater
number of patients with associated neuroinflammatory condi-
tions) in the SR cohort. Almost all patients had longstanding,
chronic bilateral disease and all but one were white. None of
those with SS disease had active uveitis by SUN criteria,9
whereas only 78% of those with SR uveitis had inactive disease
on enrollment. The proportion of patients with systemic dis-
ease, diagnosed on the basis of an appropriate subspecialist
consult, was equivalent in both groups. Prednisone use was
also equivalent at the time of enrollment, with a median dose
of 8 mg daily in the SR group and 7.5 mg daily in the SS group.
There was greater use of mycophenolate mofetil and metho-
trexate as additional immunosuppressants in patients with SR
uveitis, although tacrolimus use was similar in both cohorts.
Clinical versus In Vitro Measures of
Steroid Sensitivity
Of the 10 patients with SR disease in vitro, 9 also had clinically
SR disease, and of the 17 with in vitro SS, 12 also had clinically
SS uveitis (Table 2). This good level of agreement corresponds
to a  coefficient of 0.56 (P 0.002). Specificity and sensitivity
were 92% and 64%, respectively, giving this in vitro measure a
positive predictive value of 90% and a negative predictive value
of 71% for clinically defined disease. In a subgroup analysis of
patients with isolated ocular inflammation (n  19) and pa-
tients with associated systemic diagnoses (n  8), the positive
predictive value for SR disease was 83% and 100% respectively.
CFSE profiles for individual patients are shown in Figure 2.
Dex versus IL-2 Inhibitor Suppression of CD4
Cell Proliferation
CFSE dilution in CD4 cells from four normal volunteers in the
presence of increasing concentrations of Dex are shown in
Figure 3A. All these individuals are defined as in vitro SS on the
basis of the criteria set out in Figure 1, and although the Dex
concentration at which maximum inhibition of proliferation is
achieved varied, their CFSE profiles with supratherapeutic con-
centrations (106 M) of Dex was consistent. All had a persis-
FIGURE 1. In vitro classification of CD4 cell steroid responsiveness
in PBMC cultures exposed to 106 M dexamethasone. (A) An SR
carboxyfluorescein succinimidyl ester (CFSE) profile. The SR pheno-
type (*) was defined by the presence of a discrete subpopulation of
CFSElow cells, which had to be separated from neighboring undivided
CFSEhi cells by a central trough (t), and have a maximum height (h) at
least half that of the CFSEhi population. (B) CFSE profiles which did not
fulfill this definition were designated SS.
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tent, small CFSElow subpopulation, where the maximum CFSE
dilution was equivalent to positive control cultures (stimulated
with CD3-CD28 in the absence of Dex or IL-2 inhibition). This
finding was not an artifact of variable preculture CFSE staining,
as undivided control cells exposed to 1 mg/mL tacrolimus had
uniformly high fluorescence (Fig. 3B), suggesting that cells
escaping Dex inhibition proliferate at the same rate and there-
fore undergo the same number of divisions as untreated cells.
Conversely, the CFSE profile of cultures exposed to agents that
inhibit the generation and action of IL-2 have a very different
pattern of proliferation (Figs. 3B, 3C). They have a second CFSE
peak closely adjacent to undivided CFSEhi cells, and their max-
imum CFSE dilution reduces with increasing IL-2 inhibitor
concentration, indicating that although anti–IL-2 agents may
have less effect than Dex on the proportion of cells that go into
cycle, they more uniformly reduce the number of divisions that
each cell undergoes.
CD4 cell suppression with a combination of 108 M Dex
and an anti–IL-2 agent results in greater inhibition of prolifer-
ation than exposure to either agent alone (Fig. 3D; P  0.03).
The only exception is tacrolimus, which achieves maximum
suppression at therapeutic concentrations in the absence of
Dex.
DISCUSSION
This study demonstrates the cross-specialty relevance of the SR
T-cell phenotype by replicating the previous identification of
SR CD4 cells in UC10 in a cohort of patients with uveitis. It
also adds credence to the concept of GC-driven SR cell selec-
tion and strengthens the argument that this subpopulation of
effector T cells represents a novel target for therapeutic inter-
vention. In addition, the high level of agreement in the masked
comparison of clinical and in vitro classifications of steroid
sensitivity suggests that the reported CFSE-based assay has
potential clinical application as a predictive test of steroid
responsiveness.
This study also addresses one of the weaknesses of the
previous UC study,10 in that the control subjects were those
with clinically SS disease who were also taking systemic immu-
nosuppressants, as opposed to steroid naïve normal volun-
teers. Hence, differences observed in the study population
cannot be attributed to disparities in exogenous corticosteroid
use. However, prior in vivo exposure of PBMCs to prednisone
in the present uveitis cohort may reciprocally be a confound-
ing factor. This is also the case with the other immunosuppres-
sant treatments that were being taken by participants, but it is
counterintuitive that the greater burden of second-line agents
(in particular, mycophenolate mofetil and methotrexate) in the
SR group would have contributed to the greater degree of
CD4 cell proliferation in their cultures. Conversely, it is strik-
ing that the same SR CFSE profile observed in drug-free patients
with SR UC has been replicated in this uveitis cohort despite
their concomitant systemic immunosuppression. However,
other potential biases, such as the slightly higher proportion of
patients with intermediate uveitis and active ocular inflamma-
tion in the SR group (Table 1), cannot be resolved in the
absence of a prospective, case-matched study in treatment-
naïve patients. Differences in uveitis etiology (e.g., Behc¸et’s
versus HLA-B27–associated disease) and disease severity were
also not accounted for.
Despite these limitations, the 90% positive predictive value
of the CFSE-based assay used in this study highlights its poten-
tial clinical utility (Table 2), and although we acknowledge the
caveats associated with subgroup analyses in small patient
TABLE 2. Agreement between Clinical and In Vitro Measures of
Steroid Sensitivity
Clinical SR Clinical SS Total
In vitro SR 9 1 10
In vitro SS 5 12 17
Total 14 13 27
 coefficient  0.56 (P  0.002). Positive predictive value, 90%;
negative predictive value, 71%.
TABLE 1. Characteristics of Patients
Characteristics
Clinical Classification
SR SS
Patients, n 14 13
Median age at presentation, y
(range) 43 (21–68) 31 (21–72)
Sex, % of patients (n)
Male 28.6 (4) 38.5 (5)
Female 71.4 (10) 61.5 (8)
Race, % of patients (n)
White 100 (14) 92.3 (12)
Black 0 (0) 7.7 (1)
Classification of uveitis, % of
patients (n)
Anterior 0 (0) 7.7 (1)
Intermediate 85.8 (12) 53.8 (7)
Posterior 7.1 (1) 15.4 (2)
Pan 7.1 (1) 23.1 (3)
Systemic diagnosis, % of
patients (n)
None 71.4 (10) 69.2 (9)
Behc¸et’s disease 0 (0) 7.7 (1)
Sarcoidosis 0 (0) 15.4 (2)
Multiple sclerosis 14.4 (2) 0 (0)
Ankylosing spondylitis* 0 (0) 7.7 (1)
Other, nonspecific
neuroinflammation 7.1 (1) 0 (0)
Other, psoriasis* 7.1 (1) 0 (0)
Bilateral disease, % of patients
(n) 100 (14) 92.3 (12)
Right 0 (0) 7.7 (1)
Left 0 (0) 0 (0)
Uveitic activity, % of patients
(n)†
Active 21.4 (3) 0 (0)
Inactive 78.6 (11) 100 (13)
Systemic disease activity, % of
patients (n)†
N/A 71.4 (10) 69.2 (9)
Active 21.5 (3) 15.4 (2)
Inactive 7.1 (1) 15.4 (2)
Uveitis history
Median disease duration
prior to enrollment, y
Since start of this
episode‡ 4.3 4.4
Since first presentation 5.1 4.4
Systemic treatment, n
(median dose)†
Prednisone 13 (8 mg/d) 10 (7.5 mg/d)
Mycophenolate mofetil 11 (2 mg/d) 4 (2.5 mg/d)
Tacrolimus 7 (4 mg/d) 9 (4 mg/d)
Methotrexate 2 (12.5 mg/wk) 0 (0 mg/wk)
* Patients with ankylosing spondylitis or psoriasis did not have
associated inflammatory bowel disease
† At the time of study enrollment.
‡ This episode refers to the current period of inflammation. For
patients with recurrent disease, it started when the disease reactivated
at the end of the last period of remission. For patients with chronic
disease, it started at first presentation.
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cohorts, the positive predictive value of 83% for isolated ocular
inflammation suggests that this utility is maintained regardless
of whether there is associated systemic disease. A priori iden-
tification of the SR phenotype would enable prompt introduc-
tion of alternative immunotherapies to circumvent the require-
ment for recurrent cycles of high-dose corticosteroid rescue
after failed therapeutic taper. As such, this study reinforces that
SR T cells are a strong candidate biomarker for SR disease, with
genuine potential for translation for patient benefit. However,
whether a patient’s response to steroids is stable over time, or
is influenced by disease activity, remains to be determined.
Further investigation of the SR T-cell phenotype with the pur-
pose of development of a predictive test for SR disease is
therefore warranted.
Although the concept of an SR phenotype is relevant to a
range of autoimmune diseases,20 it does not manifest uniformly
and clinical definitions of steroid nonresponsiveness vary
across specialties. The SR threshold of 10 mg prednisone set in
this study was informed by SUN guidance, but is lower than
that used for SR UC,7 SR asthma,8 and SR rheumatoid arthri-
tis.21 Hence, the SR phenotype is unlikely to be absolute, and
any functional T-cell assay used as a measure of steroid respon-
siveness will be accordingly disease specific. (In this study the
culture conditions were preoptimized in patients with uveitis
by using lower concentrations of CD3-CD28–coated beads
[Dynabeads; Dynal, Ltd.] than that previously reported in pa-
tients with UC.) Although this emphasizes that clinical defini-
tions of SR disease and their in vitro correlates are by their
nature somewhat arbitrary, it is not at odds with the concept of
an underlying common SR drive. The degrees of T-cell receptor
stimulation and GC suppression that generate SR cells may
vary, but once selected, they comprise a defined subpopulation
that has now been identified in both SR uveitis and SR UC. As
such, their further characterization has the potential to provide
new insights into the mechanisms that underlie SR autoim-
mune inflammation, with the prospect of generating novel
therapeutic strategies to augment or potentiate corticosteroid
action. There is also potential to refine the clinical classification
of SR disease by defining prednisone thresholds in terms of
dose per unit body weight.
The accumulating evidence that IL-2 drives SR T cells10,22
is supported by the greater suppression of proliferation
observed in this study when Dex is used in combination
with anti-CD25 mAbs, than when either agent is used alone
(Fig. 3D). This finding may be explained by the complemen-
tary patterns of cell division seen in cultures of Dex and
anti-IL-2–treated cells. These patterns suggest that although
IL-2 inhibition is less effective at preventing cells from going
into cycle, it uniformly reduces the extent of proliferation in
those that do (Fig. 3B). In contrast, T cells escaping Dex
suppression proliferated to the same degree as uninhibited
control cells (Fig. 3A). This finding implies that GC suppres-
sion of T-cell proliferation is not entirely IL-2 dependent.23
Consistent with this, IL-2 inhibitors and GCs are known to
act at different points of the cell cycle, with the former
preventing activation from G0 to G1,
24 and the latter induc-
ing G1 arrest.
25,26 SR cells that continue to divide in the face
of Dex presumably therefore remain susceptible to specific
IL-2 blockade.
It is striking that despite their disparate effects (Fig. 4), each
of the anti-IL-2 agents tested induced the same pattern of T-cell
inhibition (Fig. 3B), reinforcing the assumption of their shared
mechanism of action. The similarity in the CFSE profiles from
AG490- and CD25 mAb–treated cultures also singles out the
JAK/STAT pathway as an alternative target for T-cell inhibition.
Furthermore, the enhanced suppression of CD4 cell prolifer-
ation seen when AG490 was used in combination with Dex is
in keeping with previous evidence that STAT-5 specifically
inhibits GC action by preventing nuclear translocation of its
cytosolic receptor.11
Although tacrolimus appears to be the most potent IL-2
inhibitor, its anti–T-cell effects may have been potentiated
by the inhibition of tumor necrosis factor- (TNF-) secre-
tion by monocyte-derived cells in the PBMC cultures.27 This
nonetheless reflects the in vivo tissue environment, and
such an indirect, macrophage-mediated suppression of
CD4 cell proliferation may also contribute to tacrolimus’
clinically observed steroid-sparing success, as has recently
been reported in a randomized controlled trial of tacrolimus
versus cyclosporine for the treatment of noninfectious uve-
itis.28 However, the clinical utility of the in vitro system
reported in this study as a surrogate for patients’ response to
anti–IL-2 therapies remains untested. It should therefore not
be assumed that the complete suppression of proliferation
in CD4 cells from normal volunteers observed at therapeu-
tic tacrolimus concentrations (10 ng/mL) in the absence of
Dex (Figs. 3C, 3D) will extrapolate to uveitis cohorts, in
FIGURE 2. CD4 cell proliferation
in PBMC cultures exposed to 106 M
dexamethasone. (A) Patients with
clinically SR (n 14) or (B) clinically
SS (n  13) uveitis. Light gray: in
vitro SR (*); dark gray: in vitro SS.
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which up to 40% of tacrolimus-treated patients are unable to
discontinue prednisone.29
In summary, this study has identified an SR subpopulation
of CD4 cells which is prevalent in patients with SR uveitis and
is analogous to the SR CD4 cells previously identified in
patients with SR UC. This result reinforces the concept of a
common steroid refractory phenotype which has potential
cross-specialty importance in the treatment of autoimmune
disease. There is also clear potential for using SR CD4 cells as
biomarkers of SR disease. Furthermore, the different effects of
anti–IL-2 agents and GCs on T-cell proliferation provide insight
into the mechanisms by which calcineurin inhibitors and anti-
CD25 mAbs exert their clinically observed steroid-sparing effects.
Accordingly, the characterization of SR CD4 cells has the poten-
tial to identify novel therapeutic targets for intervention in SR
disease, a prime candidate for which is JAK/STAT inhibition.
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FIGURE 4. Mechanisms of IL-2 inhibitor action. Tacrolimus (Tac) inhibits
dephosphorylation of nuclear factor of activated T cells (NFAT) by cal-
cineurin, thus preventing NFAT’s translocation to the nucleus where it
drives IL-2 transcription. Basiliximab (Bas) and daclizumab (Dac) are,
respectively, chimeric and humanized monoclonal antibodies to the
-subunit of the IL-2 receptor (CD25). AG490 inhibits the JAK/STAT
pathway downstream of CD25. IL-2 is the canonical growth factor for
T-cell division and proliferation. Dashed lines: points of inhibition.
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FIGURE 3. Dexamethasone (Dex) versus IL-2 inhibitor suppression of CD4 cell proliferation. (A) CD4 cell proliferation in PBMC cultures from
four normal volunteers (1–4) in the presence of increasing concentrations of Dex. (B) Carboxyfluorescein succinimidyl ester (CFSE) dilution in
CD4 cells from PBMC cultures exposed to increasing concentrations of IL-2 inhibitors, each of which targets a different point in the generation
and action of IL-2 (see Fig. 4). The graphs show results for one donor who was representative of four normal volunteers. (C) Suppression of CD4
cell proliferation by each IL-2 inhibitor, quantified as the proportion of undivided cells (n  4). (D) Combined Dex and IL-2 inhibitor suppression
of CD4 cell proliferation (n4). Tacrolimus (Tac), basiliximab (Bas), and daclizumab (Dac) were used at their therapeutic serum concentrations.
As AG490 is not used clinically, a dose of 1.0 g/mL was arbitrarily chosen. ve, positive control.
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